Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies.
Chakvetadze
Catherine
C
Bani-Sadr
Firouzé
F
Le Pendeven
Catherine
C
Lamontagne
Franck
F
Vincensini
Jean Paul
JP
Pialoux
Gilles
G
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000009:adverse effects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects; D014775:Virus Activation / Q000187:drug effects
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a